BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 3011242)

  • 1. Conditioned tumorigenicity of activated oncogenes.
    Klein G; Klein E
    Cancer Res; 1986 Jul; 46(7):3211-24. PubMed ID: 3011242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal translocations in B-cell derived tumors.
    Klein G
    Princess Takamatsu Symp; 1986; 17():159-70. PubMed ID: 3332008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
    Klein G
    AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
    Klein G
    Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
    Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forward and reverse changes in Ig/myc translocation carrying tumors.
    Klein G
    Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
    Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of oncogenes and suppressor genes in human neoplasia.
    Brodeur GM
    Adv Pediatr; 1987; 34():1-44. PubMed ID: 3318293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MYC impairs immunogenicity of human B cells.
    Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
    Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
    Lavialle C; Modjtahedi N; Lamonerie T; Frebourg T; Landin RM; Fossar N; Lhomond G; Cassingena R; Brison O
    Anticancer Res; 1989; 9(5):1265-79. PubMed ID: 2686529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transgenic window on lymphoid malignancy.
    Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
    Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological aspects of B-cell derived tumors in humans and rodents.
    Klein G
    Princess Takamatsu Symp; 1988; 19():3-13. PubMed ID: 2855874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translocations among antibody genes in human cancer.
    Leder P
    IARC Sci Publ; 1985; (60):341-57. PubMed ID: 4065947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
    Spandidos DA
    Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
    Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
    J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearrangement of the c-myc oncogene with heavy-chain immunoglobulin enhancer in tumor DNA from an acute lymphoblastic leukemia patient.
    Guerrasio A; Avanzi GC; Pegoraro L; Estivill X; Serra A; Giubellino MC; Fierro MT; Novarino A; Foa R; Saglio G
    J Natl Cancer Inst; 1987 May; 78(5):845-51. PubMed ID: 3106693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular oncogenes and lymphocyte activation.
    Schneider-Schaulies J; Knauer R; Schimpl A; Wecker E
    Behring Inst Mitt; 1987 Jun; (81):110-9. PubMed ID: 3115245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetics of B- and T-cell neoplasia.
    Haluska FG; Tsujimoto Y; Croce CM
    Princess Takamatsu Symp; 1986; 17():151-8. PubMed ID: 3332007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
    Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
    Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M; Neuberger MS
    Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.